| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $88M | ||
| $82M |
Buys | $0 | 0 | 0 |
Sells | $3,471,438 | 7 | 100 |
| Burrows Scott L | Chief Financial Officer | 0 | $0 | 2 | $401,259 | $-401,259 |
| Turtle Cameron | Chief Executive Officer | 0 | $0 | 5 | $3.07M | $-3.07M |
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.
Over the last 12 months, insiders at Spyre Therapeutics, Inc. have bought $0 and sold $3.47M worth of Spyre Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Spyre Therapeutics, Inc. have bought $0 and sold $2.13M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
| 2026-03-03 | Sale | Burrows Scott L | Chief Financial Officer | 2,500 0.004% | $40.65 | $101,620 | +1.15% | |
| 2026-03-02 | Sale | Turtle Cameron | Chief Executive Officer | 15,000 0.0244% | $42.19 | $632,866 | -3.36% | |
| 2026-02-02 | Sale | Turtle Cameron | Chief Executive Officer | 15,000 0.0249% | $32.80 | $492,045 | +22.10% | |
| 2026-01-02 | Sale | Turtle Cameron | Chief Executive Officer | 15,000 0.0233% | $30.68 | $460,134 | +11.10% | |
| 2025-12-01 | Sale | Turtle Cameron | Chief Executive Officer | 15,000 0.0251% | $29.02 | $435,356 | +16.77% | |
| 2025-11-03 | Sale | Turtle Cameron | Chief Executive Officer | 45,000 0.0711% | $23.33 | $1.05M | +39.36% | |
| 2025-09-02 | Sale | Burrows Scott L | Chief Financial Officer | 18,428 0.0298% | $16.26 | $299,639 | +82.38% | |
| 2024-11-06 | Sale | Albers Jeffrey W. | director | 6,700 0.0148% | $36.76 | $246,313 | -53.75% | |
| 2024-10-25 | Sale | Albers Jeffrey W. | director | 300 0.0007% | $36.43 | $10,929 | -50.33% | |
| 2024-09-03 | Sale | Burrows Scott L | Chief Financial Officer | 18,531 0.0313% | $28.17 | $522,074 | -28.80% |
| Increased Positions | 106 | +100.95% | 23M | +35.42% |
| Decreased Positions | 42 | -40% | 6M | -9.49% |
| New Positions | 31 | New | 5M | New |
| Sold Out Positions | 15 | Sold Out | 2M | Sold Out |
| Total Postitions | 169 | +60.95% | 81M | +25.93% |
| Fmr Llc | $277,059.00 | 11.62% | 9.06M | +7,110 | +0.08% | 2025-09-30 |
| Fairmount Funds Management Llc | $122,874.00 | 5.15% | 4.02M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $121,792.00 | 5.11% | 3.98M | -24,552 | -0.61% | 2025-09-30 |
| Rtw Investments, Lp | $110,761.00 | 4.64% | 3.62M | 0 | 0% | 2025-09-30 |
| Tang Capital Management Llc | $97,856.00 | 4.1% | 3.2M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $93,291.00 | 3.91% | 3.05M | -15,856 | -0.52% | 2025-09-30 |
| Vr Adviser, Llc | $82,121.00 | 3.44% | 2.69M | 0 | 0% | 2025-09-30 |
| Braidwell Lp | $78,848.00 | 3.31% | 2.58M | 0 | 0% | 2025-09-30 |
| Capital International Investors | $73,164.00 | 3.07% | 2.39M | 0 | 0% | 2025-09-30 |
| Driehaus Capital Management Llc | $63,006.00 | 2.64% | 2.06M | -25,215 | -1.21% | 2025-09-30 |